Loading…
StockAnalyzerLoading…
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company is ranked No. 42 on the 2026 Fortune 500 list of the largest United States corporations. In 2026, the company was ranked 43rd in the Forbes Global 2000. Along with Microsoft, Johnson & Johnson is one of only two U.S.-based companies that has a prime credit rating of AAA from S&P Global. Wikipedia ↗
Founders: Edward Mead Johnson, James Wood Johnson, Robert Wood Johnson I · Headquarters: New Brunswick
www.jnj.com ↗| Mr. Joaquin Duato | CEO & Chairman | 62 | 6,499,931 USD |
| Mr. Joseph James Wolk CPA | Executive VP & CFO | 58 | 3,216,428 USD |
| Dr. John C. Reed M.D., Ph.D. | Executive Vice President of Innovative Medicine and R&D | 67 | 3,165,384 USD |
| Mr. Timothy Schmid | Executive VP & Worldwide Chairman of MedTech | 55 | 2,538,167 USD |
| Mr. Robert J. Decker Jr. | Controller & Chief Accounting Officer | 52 | — |
| Mr. James Swanson | Executive VP & Chief Information Officer | 59 | — |
| Mr. Ryan Koors | Vice President of Investor Relations | — | — |
| Mr. Dirk Brinckman | Chief Compliance Officer | — | — |
| Ms. Elizabeth Forminard J.D. | Executive VP & Chief Legal Officer | 54 | — |
| Ms. Kristen Blair Mulholland | Executive VP & Chief Human Resources Officer | 58 | — |
CEOs over time (Wikidata): Joaquin Duato (2022–), Alex Gorsky (2012–2022)
| Year | Buybacks | Dividends | Acquisitions |
|---|---|---|---|
| 2022 | 6,035 | 11,682 | 17,652 |
| 2023 | 5,054 | 11,770 | -0 |
| 2024 | 2,432 | 11,823 | 15,146 |
| 2025 | 5,953 | 12,381 | 17,541 |
Shares outstanding since 2016: -11.5% 2.72 bn → 2.41 bn. Fewer shares — the company buys them back and each holder owns more.
Source: Wikidata. Year — when the company joined the group (acquired or created).
| Johnson & Johnson Pharmaceutical Research and Development | — |
| Auris Health (United States) | — |
| Johnson & Johnson (Ireland) | — |
| Johnson & Johnson (Sweden) | — |
| Johnson & Johnson (France) | — |
| Johnson & Johnson Vision Care | — |
| Johnson & Johnson (United Kingdom) | — |
| LifeScan | — |
| Alza | — |
| DePuy | — |
| Janssen Biotech | — |
| Johnson & Johnson Innovation - JJDC, Inc. | — |
| Tibotec | — |
| Johnson & Johnson Health Care Systems | — |
| Cilag AG | — |